Jasper Therapeutics Inc Financials
This page shows Jasper Therapeutics Inc (JSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Jasper remains a cash-funded development program, with R&D expansion outrunning its shrinking balance-sheet buffer.
Cash burn, financing reliance, and equity compression are now reinforcing each other: by FY2025, operating cash outflow had widened to$77.2M while cash fell to$28.7M , despite prior balance-sheet rebuilds. After sizable financing support in recent years, the company still exited FY2025 with only$4.2M of equity, implying new capital has mostly replaced consumed runway rather than creating a sturdier cushion.
Spending mix shows where the business effort sits: R&D expense reached
Liquidity and solvency are diverging: current assets of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Jasper Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Jasper Therapeutics Inc has elevated debt relative to equity (D/E of 7.62), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Jasper Therapeutics Inc's current ratio of 2.62 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.
Jasper Therapeutics Inc generates a -1826.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -115.6% the prior year.
Jasper Therapeutics Inc passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Jasper Therapeutics Inc generates $1.02 in operating cash flow (-$77.2M OCF vs -$75.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Jasper Therapeutics Inc's EBITDA was -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.6% from the prior year.
Jasper Therapeutics Inc reported -$75.8M in net income in fiscal year 2025. This represents a decrease of 6.4% from the prior year.
Jasper Therapeutics Inc earned $-3.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 19.2% from the prior year.
Cash & Balance Sheet
Jasper Therapeutics Inc held $28.7M in cash against $0 in long-term debt as of fiscal year 2025.
Jasper Therapeutics Inc had 28M shares outstanding in fiscal year 2025. This represents an increase of 86.4% from the prior year.
Margins & Returns
Jasper Therapeutics Inc's ROE was -1826.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1710.5 percentage points from the prior year.
Capital Allocation
Jasper Therapeutics Inc invested $63.1M in research and development in fiscal year 2025. This represents an increase of 13.0% from the prior year.
JSPR Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $3.6M | N/A | $9.3M | N/A | $9.8M | N/A | $8.8M | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.8M | N/A | $14.4M-32.1% | $21.2M+31.2% | $16.2M | N/A | $14.5M+28.0% | $11.3M |
| SG&A Expenses | $5.1M | N/A | $4.8M-18.8% | $5.9M+4.2% | $5.6M | N/A | $5.4M+15.7% | $4.7M |
| Operating Income | -$11.0M | N/A | -$19.2M+29.2% | -$27.1M-24.2% | -$21.8M | N/A | -$19.9M-24.4% | -$16.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.2M | N/A | -$18.7M+29.9% | -$26.7M-25.8% | -$21.2M | N/A | -$18.6M-27.8% | -$14.6M |
| EPS (Diluted) | $-0.04 | N/A | $-1.13+35.1% | $-1.74-23.4% | $-1.41 | N/A | $-1.24-27.8% | $-0.97 |
JSPR Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.2M-40.8% | $35.8M-37.7% | $57.5M+23.7% | $46.5M-19.3% | $57.6M-27.9% | $79.9M-19.6% | $99.4M-12.7% | $113.9M |
| Current Assets | $20.3M-41.4% | $34.6M-36.5% | $54.6M+27.0% | $43.0M-19.2% | $53.2M-29.9% | $75.8M-20.0% | $94.8M-12.8% | $108.7M |
| Cash & Equivalents | $14.1M-50.7% | $28.7M-43.6% | $50.9M+28.8% | $39.5M-19.0% | $48.8M-31.9% | $71.6M-22.6% | $92.5M-13.4% | $106.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $17.8M-43.8% | $31.6M-31.1% | $45.9M+99.9% | $23.0M+49.6% | $15.4M-15.8% | $18.2M+15.8% | $15.7M+15.5% | $13.6M |
| Current Liabilities | $9.0M-31.8% | $13.2M-37.3% | $21.0M+2.6% | $20.5M+66.2% | $12.3M-19.1% | $15.2M+22.3% | $12.5M+23.7% | $10.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.4M-18.1% | $4.2M-64.1% | $11.6M-50.8% | $23.5M-44.4% | $42.2M-31.5% | $61.7M-26.3% | $83.7M-16.6% | $100.3M |
| Retained Earnings | -$317.8M-0.4% | -$316.7M-3.0% | -$307.6M-6.5% | -$288.8M-10.2% | -$262.1M-8.8% | -$240.9M-11.2% | -$216.5M-9.4% | -$197.9M |
JSPR Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.5M+33.5% | -$21.9M-28.6% | -$17.0M-10.0% | -$15.5M+32.3% | -$22.8M-8.1% | -$21.1M-50.4% | -$14.1M-20.3% | -$11.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $4K | $0 | $0-100.0% | $1K-75.0% | $4K+105.3% | -$76K+72.3% | -$274K-74.5% | -$157K |
| Financing Cash Flow | N/A | -$340K-101.2% | $28.4M | N/A | N/A | $345K+3733.3% | $9K-95.0% | $181K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
JSPR Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -34.5% | N/A | -161.9%-48.2pp | -113.7%-63.4pp | -50.3% | N/A | -22.3%-7.7pp | -14.5% |
| Return on Assets | -5.5% | N/A | -32.6%+24.9pp | -57.5%-20.6pp | -36.9% | N/A | -18.8%-5.9pp | -12.8% |
| Current Ratio | 2.26-0.4 | 2.62+0.0 | 2.59+0.5 | 2.10-2.2 | 4.31-0.7 | 4.98-2.6 | 7.61-3.2 | 10.79 |
| Debt-to-Equity | 5.23-2.4 | 7.62+3.7 | 3.97+3.0 | 0.98+0.6 | 0.36+0.1 | 0.30+0.1 | 0.19+0.1 | 0.14 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Jasper Therapeutics Inc profitable?
No, Jasper Therapeutics Inc (JSPR) reported a net income of -$75.8M in fiscal year 2025.
What is Jasper Therapeutics Inc's EBITDA?
Jasper Therapeutics Inc (JSPR) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Jasper Therapeutics Inc's return on equity (ROE)?
Jasper Therapeutics Inc (JSPR) has a return on equity of -1826.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Jasper Therapeutics Inc's operating cash flow?
Jasper Therapeutics Inc (JSPR) generated -$77.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Jasper Therapeutics Inc's total assets?
Jasper Therapeutics Inc (JSPR) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Jasper Therapeutics Inc spend on research and development?
Jasper Therapeutics Inc (JSPR) invested $63.1M in research and development during fiscal year 2025.
What is Jasper Therapeutics Inc's current ratio?
Jasper Therapeutics Inc (JSPR) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.
What is Jasper Therapeutics Inc's debt-to-equity ratio?
Jasper Therapeutics Inc (JSPR) had a debt-to-equity ratio of 7.62 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Jasper Therapeutics Inc's return on assets (ROA)?
Jasper Therapeutics Inc (JSPR) had a return on assets of -211.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Jasper Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Jasper Therapeutics Inc (JSPR) had $28.7M in cash against an annual operating cash burn of $77.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Jasper Therapeutics Inc's Piotroski F-Score?
Jasper Therapeutics Inc (JSPR) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Jasper Therapeutics Inc's earnings high quality?
Jasper Therapeutics Inc (JSPR) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Jasper Therapeutics Inc?
Jasper Therapeutics Inc (JSPR) scores 8 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.